Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

aThe dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer

Authors: Gustaf Rosin, Ulf Hannelius, Linda Lindström, Per Hall, Jonas Bergh, Johan Hartman, Juha Kere

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

The dyslexia candidate gene, DYX1C1, shown to regulate and interact with estrogen receptors and involved in the regulation of neuronal migration, has recently been proposed as a putative cancer biomarker. This study was undertaken to assess the prognostic value and therapy-predictive potential of DYX1C1 mRNA and protein expression in breast cancer.

Methods

DYX1C1 mRNA expression was assessed at the mRNA level in three independent population-derived patient cohorts. An association to estrogen/progesterone receptor status, Elston grade, gene expression subtype and lymph node status was analyzed within these cohorts. DYX1C1 protein expression was examined using immunohistochemistry in cancer and normal breast tissue. The statistical analyses were performed using the non-parametric Wilcoxon rank-sum test, ANOVA, Fisher's exact test and a multivariate proportional hazard (Cox) model.

Results

DYX1C1 mRNA is significantly more highly expressed in tumors that have been classified as estrogen receptor α and progesterone receptor-positive. The expression of DYX1C1 among the molecular subtypes shows the lowest median expression within the basal type tumors, which are considered to have the worst prognosis. The expression of DYX1C1 is significantly lower in tumors graded as Elston grade 3 compared with grades 1 and 2. DYX1C1 protein is expressed in 88% of tumors and in all 10 normal breast tissues examined. Positive protein expression was significantly correlated to overall survival (Hazard ratio 3.44 [CI 1.84-6.42]) of the patients but not to any of the variables linked with mRNA expression.

Conclusion

We show that the expression of DYX1C1 in breast cancer is associated with several clinicopathological parameters and that loss of DYX1C1 correlates with a more aggressive disease, in turn indicating that DYX1C1 is a potential prognostic biomarker in breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
2.
go back to reference Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005, 102 (38): 13550-13555. 10.1073/pnas.0506230102.CrossRefPubMedPubMedCentral Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005, 102 (38): 13550-13555. 10.1073/pnas.0506230102.CrossRefPubMedPubMedCentral
3.
go back to reference Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009, 20 (8): 1319-1329. 10.1093/annonc/mdp322.CrossRefPubMedPubMedCentral Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009, 20 (8): 1319-1329. 10.1093/annonc/mdp322.CrossRefPubMedPubMedCentral
4.
go back to reference Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirstrom K, Blomqvist C, Amini RM, Fjallskog ML: Cyclin a is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009, 18 (9): 2501-2506. 10.1158/1055-9965.EPI-09-0169.CrossRefPubMed Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirstrom K, Blomqvist C, Amini RM, Fjallskog ML: Cyclin a is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009, 18 (9): 2501-2506. 10.1158/1055-9965.EPI-09-0169.CrossRefPubMed
5.
go back to reference Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351 (9114): 1451-1467.CrossRef Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351 (9114): 1451-1467.CrossRef
6.
go back to reference Johnston SR: New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010, 16 (7): 1979-1987. 10.1158/1078-0432.CCR-09-1823.CrossRefPubMed Johnston SR: New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010, 16 (7): 1979-1987. 10.1158/1078-0432.CCR-09-1823.CrossRefPubMed
7.
go back to reference Kim YJ, Huh JW, Kim DS, Bae MI, Lee JR, Ha HS, Ahn K, Kim TO, Song GA, Kim HS: Molecular characterization of the DYX1C1 gene and its application as a cancer biomarker. J Cancer Res Clin Oncol. 2009, 135 (2): 265-270. 10.1007/s00432-008-0445-8.CrossRefPubMed Kim YJ, Huh JW, Kim DS, Bae MI, Lee JR, Ha HS, Ahn K, Kim TO, Song GA, Kim HS: Molecular characterization of the DYX1C1 gene and its application as a cancer biomarker. J Cancer Res Clin Oncol. 2009, 135 (2): 265-270. 10.1007/s00432-008-0445-8.CrossRefPubMed
8.
go back to reference Chen Y, Zhao M, Wang S, Chen J, Wang Y, Cao Q, Zhou W, Liu J, Xu Z, Tong G, et al: A novel role for DYX1C1, a chaperone protein for both Hsp70 and Hsp90, in breast cancer. J Cancer Res Clin Oncol. 2009, 135 (9): 1265-1276. 10.1007/s00432-009-0568-6.CrossRefPubMed Chen Y, Zhao M, Wang S, Chen J, Wang Y, Cao Q, Zhou W, Liu J, Xu Z, Tong G, et al: A novel role for DYX1C1, a chaperone protein for both Hsp70 and Hsp90, in breast cancer. J Cancer Res Clin Oncol. 2009, 135 (9): 1265-1276. 10.1007/s00432-009-0568-6.CrossRefPubMed
9.
go back to reference Taipale M, Kaminen N, Nopola-Hemmi J, Haltia T, Myllyluoma B, Lyytinen H, Muller K, Kaaranen M, Lindsberg PJ, Hannula-Jouppi K, et al: A candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide repeat domain protein dynamically regulated in brain. Proc Natl Acad Sci USA. 2003, 100 (20): 11553-11558. 10.1073/pnas.1833911100.CrossRefPubMedPubMedCentral Taipale M, Kaminen N, Nopola-Hemmi J, Haltia T, Myllyluoma B, Lyytinen H, Muller K, Kaaranen M, Lindsberg PJ, Hannula-Jouppi K, et al: A candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide repeat domain protein dynamically regulated in brain. Proc Natl Acad Sci USA. 2003, 100 (20): 11553-11558. 10.1073/pnas.1833911100.CrossRefPubMedPubMedCentral
10.
go back to reference Tapia-Paez I, Tammimies K, Massinen S, Roy AL, Kere J: The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia. FASEB J. 2008, 22 (8): 3001-3009. 10.1096/fj.07-104455.CrossRefPubMedPubMedCentral Tapia-Paez I, Tammimies K, Massinen S, Roy AL, Kere J: The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia. FASEB J. 2008, 22 (8): 3001-3009. 10.1096/fj.07-104455.CrossRefPubMedPubMedCentral
11.
go back to reference Gabel LA, Gibson CJ, Gruen JR, Loturco JJ: Progress towards a cellular neurobiology of reading disability. Neurobiol Dis. 2010, 38 (2): 173-180. 10.1016/j.nbd.2009.06.019.CrossRefPubMed Gabel LA, Gibson CJ, Gruen JR, Loturco JJ: Progress towards a cellular neurobiology of reading disability. Neurobiol Dis. 2010, 38 (2): 173-180. 10.1016/j.nbd.2009.06.019.CrossRefPubMed
12.
go back to reference Massinen S, Tammimies K, Tapia-Paez I, Matsson H, Hokkanen ME, Soderberg O, Landegren U, Castren E, Gustafsson JA, Treuter E, et al: Functional interaction of DYX1C1 with estrogen receptors suggests involvement of hormonal pathways in dyslexia. Hum Mol Genet. 2009, 18 (15): 2802-2812. 10.1093/hmg/ddp215.CrossRefPubMed Massinen S, Tammimies K, Tapia-Paez I, Matsson H, Hokkanen ME, Soderberg O, Landegren U, Castren E, Gustafsson JA, Treuter E, et al: Functional interaction of DYX1C1 with estrogen receptors suggests involvement of hormonal pathways in dyslexia. Hum Mol Genet. 2009, 18 (15): 2802-2812. 10.1093/hmg/ddp215.CrossRefPubMed
13.
go back to reference Rosen GD, Bai J, Wang Y, Fiondella CG, Threlkeld SW, LoTurco JJ, Galaburda AM: Disruption of neuronal migration by RNAi of Dyx1c1 results in neocortical and hippocampal malformations. Cereb Cortex. 2007, 17 (11): 2562-2572. 10.1093/cercor/bhl162.CrossRefPubMedPubMedCentral Rosen GD, Bai J, Wang Y, Fiondella CG, Threlkeld SW, LoTurco JJ, Galaburda AM: Disruption of neuronal migration by RNAi of Dyx1c1 results in neocortical and hippocampal malformations. Cereb Cortex. 2007, 17 (11): 2562-2572. 10.1093/cercor/bhl162.CrossRefPubMedPubMedCentral
14.
go back to reference Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, Magnusson C: Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006, 15 (12): 2482-2488. 10.1158/1055-9965.EPI-06-0489.CrossRefPubMed Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, Magnusson C: Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006, 15 (12): 2482-2488. 10.1158/1055-9965.EPI-06-0489.CrossRefPubMed
15.
go back to reference Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88 (3-4): 173-182. 10.1093/jnci/88.3-4.173.CrossRefPubMed Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88 (3-4): 173-182. 10.1093/jnci/88.3-4.173.CrossRefPubMed
16.
go back to reference Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7 (6): R953-R964. 10.1186/bcr1325.CrossRefPubMedPubMedCentral Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7 (6): R953-R964. 10.1186/bcr1325.CrossRefPubMedPubMedCentral
17.
go back to reference Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA: Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006, 66 (23): 11207-11213. 10.1158/0008-5472.CAN-06-0017.CrossRefPubMed Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA: Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006, 66 (23): 11207-11213. 10.1158/0008-5472.CAN-06-0017.CrossRefPubMed
18.
go back to reference Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66 (21): 10292-10301. 10.1158/0008-5472.CAN-05-4414.CrossRefPubMed Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66 (21): 10292-10301. 10.1158/0008-5472.CAN-05-4414.CrossRefPubMed
19.
go back to reference Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17 (5): 1474-1481.PubMed Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17 (5): 1474-1481.PubMed
20.
go back to reference Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, le Roanh D, To TV, Qian Z, Love RR, Allred DC: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004, 17 (12): 1545-1554. 10.1038/modpathol.3800229.CrossRefPubMed Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, le Roanh D, To TV, Qian Z, Love RR, Allred DC: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004, 17 (12): 1545-1554. 10.1038/modpathol.3800229.CrossRefPubMed
21.
go back to reference Schoenfeld D: Partial residuals for the proportional hazards regression model. Biometrika. 1982, 69: 239-241. 10.1093/biomet/69.1.239.CrossRef Schoenfeld D: Partial residuals for the proportional hazards regression model. Biometrika. 1982, 69: 239-241. 10.1093/biomet/69.1.239.CrossRef
22.
go back to reference R Development Core Team: R: A language and environment for statistical computing. 2009, Vienna, Austria: R Foundation for Statistical Computing R Development Core Team: R: A language and environment for statistical computing. 2009, Vienna, Austria: R Foundation for Statistical Computing
23.
go back to reference Courtillot C, Plu-Bureau G, Binart N, Balleyguier C, Sigal-Zafrani B, Goffin V, Kuttenn F, Kelly PA, Touraine P: Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005, 10 (4): 325-335. 10.1007/s10911-006-9006-4.CrossRefPubMed Courtillot C, Plu-Bureau G, Binart N, Balleyguier C, Sigal-Zafrani B, Goffin V, Kuttenn F, Kelly PA, Touraine P: Benign breast diseases. J Mammary Gland Biol Neoplasia. 2005, 10 (4): 325-335. 10.1007/s10911-006-9006-4.CrossRefPubMed
24.
go back to reference Bombonati A, Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 2011, 223 (2): 307-317.CrossRefPubMed Bombonati A, Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 2011, 223 (2): 307-317.CrossRefPubMed
25.
go back to reference Espina V, Liotta LA: What is the malignant nature of human ductal carcinoma in situ?. Nat Rev Cancer. 2011, 11 (1): 68-75. 10.1038/nrc2950.CrossRefPubMed Espina V, Liotta LA: What is the malignant nature of human ductal carcinoma in situ?. Nat Rev Cancer. 2011, 11 (1): 68-75. 10.1038/nrc2950.CrossRefPubMed
26.
go back to reference Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004, 6 (1): 17-32. 10.1016/j.ccr.2004.06.010.CrossRefPubMed Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004, 6 (1): 17-32. 10.1016/j.ccr.2004.06.010.CrossRefPubMed
27.
go back to reference Begley LA, MacDonald JW, Day ML, Macoska JA: CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem. 2007, 282 (37): 26767-26774. 10.1074/jbc.M700440200.CrossRefPubMed Begley LA, MacDonald JW, Day ML, Macoska JA: CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem. 2007, 282 (37): 26767-26774. 10.1074/jbc.M700440200.CrossRefPubMed
28.
go back to reference Patury S, Miyata Y, Gestwicki JE: Pharmacological targeting of the Hsp70 chaperone. Curr Top Med Chem. 2009, 9 (15): 1337-1351. 10.2174/156802609789895674.CrossRefPubMedPubMedCentral Patury S, Miyata Y, Gestwicki JE: Pharmacological targeting of the Hsp70 chaperone. Curr Top Med Chem. 2009, 9 (15): 1337-1351. 10.2174/156802609789895674.CrossRefPubMedPubMedCentral
29.
go back to reference Wang Y, Paramasivam M, Thomas A, Bai J, Kaminen-Ahola N, Kere J, Voskuil J, Rosen GD, Galaburda AM, Loturco JJ: DYX1C1 functions in neuronal migration in developing neocortex. Neuroscience. 2006, 143 (2): 515-522. 10.1016/j.neuroscience.2006.08.022.CrossRefPubMed Wang Y, Paramasivam M, Thomas A, Bai J, Kaminen-Ahola N, Kere J, Voskuil J, Rosen GD, Galaburda AM, Loturco JJ: DYX1C1 functions in neuronal migration in developing neocortex. Neuroscience. 2006, 143 (2): 515-522. 10.1016/j.neuroscience.2006.08.022.CrossRefPubMed
30.
go back to reference Rakha EA, Reis-Filho JS, Ellis IO: Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010, 120 (2): 293-308. 10.1007/s10549-010-0746-x.CrossRefPubMed Rakha EA, Reis-Filho JS, Ellis IO: Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010, 120 (2): 293-308. 10.1007/s10549-010-0746-x.CrossRefPubMed
31.
go back to reference Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19 (5): 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
32.
go back to reference Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, et al: Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol. 2010, 177 (5): 2323-2333. 10.2353/ajpath.2010.100209.CrossRefPubMedPubMedCentral Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, et al: Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol. 2010, 177 (5): 2323-2333. 10.2353/ajpath.2010.100209.CrossRefPubMedPubMedCentral
33.
go back to reference Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, et al: Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol. 2010, 177 (5): 2323-2333. 10.2353/ajpath.2010.100209.CrossRefPubMedPubMedCentral Stein T, Cosimo E, Yu X, Smith PR, Simon R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, et al: Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol. 2010, 177 (5): 2323-2333. 10.2353/ajpath.2010.100209.CrossRefPubMedPubMedCentral
34.
go back to reference Legg JA, Herbert JM, Clissold P, Bicknell R: Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008, 11 (1): 13-21. 10.1007/s10456-008-9100-x.CrossRefPubMed Legg JA, Herbert JM, Clissold P, Bicknell R: Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008, 11 (1): 13-21. 10.1007/s10456-008-9100-x.CrossRefPubMed
35.
go back to reference Schmid BC, Rezniczek GA, Fabjani G, Yoneda T, Leodolter S, Zeillinger R: The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat. 2007, 106 (3): 333-342. 10.1007/s10549-007-9504-0.CrossRefPubMed Schmid BC, Rezniczek GA, Fabjani G, Yoneda T, Leodolter S, Zeillinger R: The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. Breast Cancer Res Treat. 2007, 106 (3): 333-342. 10.1007/s10549-007-9504-0.CrossRefPubMed
Metadata
Title
aThe dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer
Authors
Gustaf Rosin
Ulf Hannelius
Linda Lindström
Per Hall
Jonas Bergh
Johan Hartman
Juha Kere
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-79

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine